• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Genentech Provides Update on Phase III MARIANNE Study in People with Previously Untreated Advanced HER2-Positive Breast Cancer

    Genentech Provides Update on Phase III MARIANNE Study in People with Previously Untreated Advanced HER2-Positive Breast Cancer

  2. Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma

    Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma

  3. Roche Names New Genentech R&D Chief

    Roche Names New Genentech R&D Chief

  4. Roche Names New Genentech Chief

    Roche Names New Genentech Chief

  5. Genentech Submits New Drug Application to FDA for Investigational Cobimetinib Used in Combination With Zelboraf (vemurafenib) in Advanced Melanoma

    Genentech Submits New Drug Application to FDA for Investigational Cobimetinib Used in Combination With Zelboraf (vemurafenib) in Advanced Melanoma

  6. Genentech to Present Clinical Data from Six Different Medicines at American Society of Hematology (ASH) Annual Meeting

    Genentech to Present Clinical Data from Six Different Medicines at American Society of Hematology (ASH) Annual Meeting

  7. Bina Technologies is acquired by Roche.

    Bina Technologies is acquired by Roche.

  8. ImmunoGen Reports Roche Has Provided an Update on the MARIANNE Trial

    ImmunoGen Reports Roche Has Provided an Update on the MARIANNE Trial

  9. Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

    Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

  10. Cerulean Announces First Patient Dosed with CRLX301 in Phase 1/2a Trial in Advanced Solid Tumors

    Cerulean Announces First Patient Dosed with CRLX301 in Phase 1/2a Trial in Advanced Solid Tumors

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.